Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
PPARA Antibody
Purified Mouse Monoclonal Antibody (Mab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| IHC-P, IF, FC, WB |
|---|---|
| Primary Accession | Q07869 |
| Reactivity | Human, Mouse |
| Host | Mouse |
| Clonality | Monoclonal |
| Calculated MW | H=52;M=52 KDa |
| Isotype | IgG1,κ |
| Antigen Source | HUMAN |
| Gene ID | 5465 |
|---|---|
| Other Names | Peroxisome proliferator-activated receptor alpha, PPAR-alpha, Nuclear receptor subfamily 1 group C member 1, PPARA, NR1C1, PPAR |
| Dilution | IF~~1:25 WB~~1:500 IHC-P~~1:25 FC~~1:25 |
| Target/Specificity | This PPARA antibody is generated from a mouse immunized with a recombination protein from the human region of human PPARA. |
| Format | Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, followed by dialysis against PBS. |
| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | PPARA Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | PPARA |
|---|---|
| Synonyms | NR1C1, PPAR |
| Function | Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn- glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety. Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as a transcription activator for the ACOX1 and P450 genes. Transactivation activity requires heterodimerization with RXRA and is antagonized by NR2C2. May be required for the propagation of clock information to metabolic pathways regulated by PER2. |
| Cellular Location | Nucleus. |
| Tissue Location | Skeletal muscle, liver, heart and kidney. Expressed in monocytes (PubMed:28167758). |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl- 2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety (By similarity). Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the ACOX1 and P450 genes. Transactivation activity requires heterodimerization with RXRA and is antagonized by NR2C2.
References
Sher T.,et al.Biochemistry 32:5598-5604(1993).
Mukherjee R.,et al.J. Steroid Biochem. Mol. Biol. 51:157-166(1994).
Tugwood J.D.,et al.Ann. N. Y. Acad. Sci. 804:252-265(1996).
Kobayashi T.,et al.FEBS Lett. 582:2737-2744(2008).
Cho M.-C.,et al.Immunopharmacol. Immunotoxicol. 31:459-467(2009).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
